AHK-Cu vs Minoxidil
Well Studied vs FDA Approved
synergistic Researched · 95% Both promote hair growth via different mechanisms - minoxidil via potassium channel opening and vasodilation, AHK-Cu via dermal papilla stimulation.
Molecular Data
AHK-Cu Minoxidil
Weight 416.9 Da 209.25 Da
Half-life Not established ~4 hours (oral); topical effects persist significantly longer due to local tissue retention
Chain 3 amino acids —
Type Copper tripeptide complex Synthetic pyrimidine derivative (6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine)
Key Benefits
AHK-Cu
01 Hair follicle elongation stimulation
02 Dermal papilla cell proliferation
03 VEGF upregulation for improved scalp circulation
04 TGF-β1 reduction (counters DHT effects)
05 Anti-apoptotic protection for follicles
06 Collagen synthesis support
07 Convenient topical application
08 Fibroblast activation for skin regeneration
Minoxidil
01 FDA-approved for androgenetic alopecia with decades of clinical evidence
02 Stimulates new hair growth and increases hair follicle size independent of androgen pathways
03 Available over the counter as a topical treatment without a prescription
04 Effective in both men and women for pattern hair loss
05 Low-dose oral formulation offers a convenient once-daily alternative to twice-daily topical application
06 Synergistic with finasteride and dutasteride for a multi-mechanism approach to hair loss
07 Extends the anagen (growth) phase and shortens the telogen (resting) phase of the hair cycle
Dosing Protocols
AHK-Cu
0.5-1% topical solution/serum / Once or twice daily application
Mesotherapy - Scalp (Practitioner) 0.1-0.5 mg per injection site Weekly sessions
Research Protocol 1-5 mg 2-3 times weekly
Minoxidil
Topical: 1mL of 5% solution twice daily / Oral: 1.25-2.5mg daily / Twice daily (topical) or once daily (oral)
Side Effects
AHK-Cu
Generally well-tolerated with excellent safety profile in topical applications
Rare scalp irritation (patch test recommended)
Potential for mild redness on sensitive skin
Minoxidil
Scalp irritation, dryness, or flaking (topical, especially solution formulations containing propylene glycol)
Initial shedding phase during the first 1-3 months of treatment
Hypertrichosis (unwanted facial and body hair growth, more common with oral administration)
Fluid retention and mild peripheral edema (oral)
Mild dizziness or lightheadedness upon standing (oral, due to vasodilation)
Contraindications
Not for use on broken or infected skin
Avoid eye area - may cause irritation
Do not use if allergic to copper or peptides
Not recommended during acute skin infections
Known hypersensitivity to minoxidil or any component of the formulation
Pheochromocytoma (minoxidil may stimulate catecholamine release)
Significant cardiovascular disease, including history of pericardial effusion or congestive heart failure
Concurrent use of potent antihypertensive medications without physician supervision (risk of additive hypotension)
Pregnancy and breastfeeding (Category C; oral minoxidil has shown evidence of fetal harm in animal studies)
Research Evidence
AHK-Cu Minoxidil
Status Well Studied FDA Approved
References 4 studies 5 studies
Latest March 2025 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.